方盛制药周晓莉：坚定研发引领 聚焦中药创新药发展

Core Viewpoint - The Chinese pharmaceutical industry is increasingly focusing on innovation, with leading companies like Fangsheng Pharmaceutical adopting a research-driven development approach, supported by favorable policies for traditional Chinese medicine (TCM) innovation drugs [2][3]. Group 1: Product Launch and Market Strategy - Fangsheng Pharmaceutical launched its new product, "Yangxue Qufeng Zhitong Granules," which is the first TCM innovation drug for frequent tension-type headaches, and it has been included in the national medical insurance directory [3][4]. - The company aims to cover over 500 public medical institutions by 2026 and achieve sales revenue exceeding that of its previous TCM innovation drug, "Xuanqi Jianguo Pian" [3][4]. Group 2: R&D Focus and Pipeline - Fangsheng Pharmaceutical is concentrating on innovative TCM research while also developing modified TCM drugs and chemical generics, with plans to explore chemical and biological innovation drugs [4][5]. - The company has a growing product pipeline, including several TCM innovation drugs that have received clinical trial approvals, such as "Yiqi Xiaoliu Granules" and "Ziying Granules" [4][5]. Group 3: Financial Performance and Shareholder Returns - Since its listing, Fangsheng Pharmaceutical has distributed dividends 17 times, totaling approximately 689 million yuan (including tax), and has implemented multiple dividend distributions annually since 2020 [6]. - The company is focusing on enhancing its operational capabilities and product market access to support its growth strategy [6][7]. Group 4: Industrial Hemp Development - Fangsheng Pharmaceutical's subsidiary, Yunnan Fuya Biotechnology Co., has achieved large-scale production of high-purity CBD and is expanding its global market presence [6][7]. - The company is adopting a combination of commissioned and independent research and development strategies to broaden the application scenarios of industrial hemp products [7].